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The objective of this study was to investigate in vitro the interactions between novel epi-
dermal growth factor receptor kinase inhibitors (EGFRIs) developed for positron emission
tomography (PET) imaging and themajor efﬂux transporter breast cancer resistance protein
(BCRP/ABCG2). Seven compounds were evaluated, using the ATPase activity assays
and Madin-Darbey canine kidney (MDCK) cells overexpressing BCRP. Five of the tested
compounds activated BCRP ATPase to various extent. Overexpression of BCRP conferred
resistance to ML04, ML06, methoxy-Br-ML03, and PEG6-ML05 (IC50 values for inhibition
of control cell proliferation 2.1 ± 0.6, 2.2 ± 0.7, 1.8 ± 1.2, and 2.8 ± 3.1 μM, respectively,
compared to >50 μM in MDCK-BCRP cells). At submicromolar concentrations, none
of the EGFRIs signiﬁcantly inhibited BCRP. Immunoblotting studies indicated that BCRP
expression is evident in cell lines utilized for in vivo tumor grafting in small animal PET
imaging studies. Thus, the intensity of EGFRIs radioactivity signals previously observed
in tumor xenografts reﬂects an interplay between transporter-mediated distribution of the
probe into tumor cells and target binding. Concomitant use of efﬂux transporter inhibitors
may help distinguish between the contribution of efﬂux transport and EGFR binding to the
tissue signal.
Keywords: epidermal growth factor receptor, epidermal growth factor receptor kinase inhibitors, breast cancer
resistance protein, P -glycoprotein, imaging, positron emission tomography
INTRODUCTION
Receptor tyrosine kinases play a key role in vital cellular functions,
such as cell growth, differentiation, proliferation, and survival.
Therefore, it is not surprising that enhanced activity of tyro-
sine kinases can lead to proliferative disease, including malignant
tumors (Levitzki and Gazit, 1995; Levitzki and Mishani, 2006;
Yarden and Pines, 2012). Accordingly, inhibition of hyperactive
tyrosine kinase signaling pathways has emerged as a promis-
ing strategy for the treatment of cancer, and several TKIs
have been approved by the FDA (Levitzki and Mishani, 2006;
Mishani and Hagooly, 2009; Poot et al., 2013). Nevertheless,
response rate is highly variable, in particular among patients
treated with small-molecule TKIs directed against the EGFR
(Poot et al., 2013).
The most established cause of secondary resistance is
the occurrence of mutations in the catalytic domain of the
kinase, which restrict the binding of currently available TKIs
(Levitzki and Mishani, 2006). In addition, primary or secondary
resistance may result from insufﬁcient intracellular drug concen-
trations, due to poor uptake (Wang et al., 2008; Engler et al.,
2011; Mandery et al., 2012) or active efﬂux transport (Ozvegy-
Laczka et al., 2005; Eadie et al., 2014). Two prominent transporters
involved in drug efﬂux from cells are P-gp (multidrug resistance
Abbreviations: ABC, adenosine triphosphate binding cassette; BCRP, breast can-
cer resistance protein; EGFR, epidermal growth factor receptor; EGFRI, epidermal
growth factor receptor kinase inhibitor; FTC, fumitremorgin C; PET, positron
emission tomography; P-gp, P-glycoprotein; TKI, tyrosine kinase inhibitor.
protein 1) and the BCRP (ABCG2), members of the ABC
family of membrane transporters (Szakács et al., 2006). P-gp
and BCRP are expressed in tissues involved in drug absorption
and elimination (intestine, liver, and kidney) and in barri-
ers to drug distribution, such as the blood–brain barrier and
the placenta. Hence, they play a key role in the pharmacoki-
netics of substrate drugs (Eyal et al., 2009). These transporters
have also been implicated in multidrug resistance due to active
removal of chemotherapeutic agents from tumor cells. P-gp
and BCRP substrates include TKIs, although the relative afﬁni-
ties and the nature of interaction with ABC transporters vary
among these compounds (Eadie et al., 2014). For example, geﬁ-
tinib is a BCRP transported substrate and inhibitor at low
concentrations (Ozvegy-Laczka et al., 2004), whereas nilotinib
appears to be a BCRP transported substrate at submicromolar
concentrations and an inhibitor at micromolar concentrations
(Eadie et al., 2014).
Due to the variability in EGFRIs pharmacokinetics and patient
response, PET imaging with radiolabeled EGFRIs has emerged
as an important tool in the development of these compounds
(Levitzki and Mishani, 2006; Mishani and Hagooly, 2009; Slobbe
et al., 2012). Initial PET studies with ﬂuorine-18-labeled reversible
EGFR inhibitors in tumor-bearing animals demonstrated rela-
tively low uptake or fast clearance of the reversible EGFRIs from
the tumor area, at least in part due to active efﬂux from tumor
cells (Mishani et al., 2008; Slobbe et al., 2012). Nevertheless, the
interaction of geﬁtinib (Kawamura et al., 2009) and sorafenib
(Asakawa et al., 2011) with P-gp and BCRP has become the basis
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for their evaluation asPETprobes of the functional activity of these
transporters at the blood-brain barrier, in which they restrict drug
distribution into the brain (Eyal et al., 2009).
In order to enhance treatment and imaging efﬁciency, irre-
versible EGFR kinase inhibitors were developed on the basis
of 4-(phenylamino) quinazoline and quinoline core structures
(Mishani et al., 2004, 2005, 2008; Shaul et al., 2004;Abourbeh et al.,
2007; Dissoki et al., 2007; Mishani and Hagooly, 2009). However,
the tumor uptake of some of these compounds was modest, and
one of them, the irreversible EGFRI ML04, was found to be a P-gp
substrate (Abourbeh et al., 2007).
Here, we evaluated in vitro the interactions of seven
novel EGFRI developed as PET bioprobes with BCRP, in
order to better understand the factors that affect their biodis-
tribution. The evaluated compounds were ML04 (Mishani
et al., 2004; Abourbeh et al., 2007); ML05 and PEG6-ML05
(Dissoki et al., 2007); ML06 (Shaul et al., 2004); methoxy-
ML03 and N-{4-[(3-Bromo-phenyl)amino]-quinazoline-6-yl}-2-
methoxyacetamide (“methoxy-Br-ML03”; Mishani et al., 2005);
and ML10 (Mishani et al., 2008; Figure 1). The selected com-
pounds represent those with high vs. low EGFR binding potency
(e.g., IC50 = 0.05–5 nM, 10 nM, 30–45 nM, and 252 nM for
ML06, ML04/ML05, PEG6-ML05, and methoxy-ML03, respec-
tively, in A431 cell lysates; Shaul et al., 2004; Mishani et al., 2005;
Dissoki et al., 2007) and various degrees of lipophilicity (e.g., Log
P 3.9 for ML04, 4.12 for ML05, and 4.75 for PEG6-ML05; Dissoki
et al., 2007).
MATERIALS AND METHODS
MATERIALS
The EGFRIs used in these experiments were kindly provided
by Prof. Eyal Mishani (Department of Medical Biophysics
and Nuclear Medicine, Hadassah-Hebrew University, Jerusalem,
Israel). Geﬁtinib, the positive control, was purchased from Tocris
Bioscience (Bristol, UK). BODIPY-prazosin was from Molecular
Probes (Grand Island, NY, USA). The bicinchoninic acid (BCA)
assay reagent kit was from Pierce (Rockford, IL, USA; Thermo
Scientiﬁc). Skim milk was from Difco BD (Le Pont de Claix,
France). Nitrocellulose membranes were from Whatman GmbH
(Dassel, Germany). Cell culture reagents were from Biological
Industries (Beit Haemek, Israel). All the other reagents were from
Sigma–Aldrich (Rehovot, Israel).
CELL CULTURES
Madin-Darbey canine kidney (MDCK) cells transfected with
pcDNA empty vector (MDCK-pcDNA3; MDCK-CT) and cDNA
coding for wild-type BCRP (MDCK-BCRP) cells were a generous
gift from Prof. Qingcheng Mao (University of Washington, Seat-
tle, WA, USA). The human lung carcinoma cell lines A549 and
HCC827 cells were provided by Prof. Eyal Mishani.
Madin-Darbey canine kidney vector (MDCK-pcDNA3) and
MDCK-BCRP cells were grown in Eagle’s minimum essential
medium (MEM) supplemented with 10% fetal bovine serum,
2 mM L-glutamine, 100 units/mL penicillin, and 100 μg/mL
streptomycin, at 37◦C and 5% CO2-humidiﬁed incubator.
The BCRP positive cells were selected by supplementation of
0.05 mg/mL gentamicin to the growth medium. The adher-
ent cells, continuously cultivated in 10 cm2 cell culture plates,
were grown to nearly 80–90% conﬂuence before they were
harvested by trypsin-EDTA 0.25% solution. A549 were grown
in Ham’s F12 growth medium and HCC827 were grown in
RPMI-1640 growth medium. The cells were treated as described
above.
ATPase ASSAY
ATPase activity was evaluated using PREDEASY kits (SOLVO
Biotechnology, Szeged,Hungary), according to themanufacturer’s
instructions.
WESTERN BLOT ANALYSIS
Western blot analysis was conducted as described before (Port-
noy et al., 2012). Brieﬂy, whole cell lysates were resuspended in
200 μl ice-cold lysis buffer and were shaken for 1 h at 4◦C. Then,
the lysate was centrifuged at 15,100 g for 15 min at 4◦C. Pro-
tein concentrations were quantiﬁed by the BCA protein assay
reagent kit according to the manufacturer’s instructions. Samples
were run on a graded gel composed of a lower 10% separat-
ing gel layer and an upper 5% stacking gel layer. Gels were
FIGURE 1 | Chemical structure of compounds investigated in this study.
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electrotransferred to nitrocellulose membranes and membranes
were blocked in blocking buffer for 1 h at room temperature
with gentle shaking, then washed three times with tris-buffered
saline with tween 20 (TBST) for 5 min. Membranes were probed
overnight at 4◦C with BXP-21 BCRP antibody at 1:250 and
anti β-actin 1:2500. The membranes were washed three times
with TBST for 10 min at room temperature, then incubated
with horse radish peroxidase (HRP)-conjugated goat anti-rabbit
secondary antibodies or goat anti-mouse IgG at 1:10000 for
1 h at room temperature. Following incubation, membranes
were developed by enhanced chemiluminescence (ECL) detection
and exposed to FUJI Medical Super RX X-ray ﬁlms (Fujiﬁlms,
Tokyo, Japan).
ACCUMULATION ASSAYS
Accumulation assays with ﬂuorescent substrates of efﬂux trans-
porter are commonly utilized to determine the inhibitory effect
of a test compound (Brouwer et al., 2013). In this study, MDCK-
CT and MDCK-BCRP cells were seeded at density of 20 × 104
cells/well in 24 well plates. Experiments were performed two
days after achieving 100% conﬂuent monolayers. Prior to the
experiment, the medium was removed and cells were incubated
for 1 h with one of the test compounds dissolved in DMEM
with 5 mM 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), pH 7.4. In the accumulation phase cells were co-
incubated with 500 nM BODIPY-prazosin (a BCRP/P-gp sub-
strate; Dey et al., 1997; Ni et al., 2010) and one of the test
compounds dissolved in DMEM with 5 mM HEPES. After 1 h,
the cells were washed three times with ice-cold PBS. Intracel-
lular ﬂuorescence intensity of BODIPY-prazosin was measured
within 1 h by a plate reader (Synergy HT, BioTek, Winooski, VT,
USA)with excitationwavelength 485 nmand emissionwavelength
528 nm.
MTT CELL PROLIFERATION ASSAYS
The assay was performed as described earlier (Rajendra et al.,
2003) with minor modiﬁcations. Brieﬂy, Cells were seeded at
density of 80 × 103 cells per well in 24 well plates. On the
following day, the cells were incubated (in hexaplicates) with 0.2–
102.4 μM of the tested EGFRIs or with the vehicle in the growth
medium for 72 h. Then, the medium was removed and 300 μl
of 0.5 mg/mL MTT solution in Hank’s Balanced Salt Solution
(HBSS) was added to each well. After 2 h incubation at 37◦C, the
MTT solution was removed and the cells were washed three times
with HBSS, then the culture plates were incubated with 500 μl
dimethyl sulphoxide (DMSO) for 15 min at room temperature.
The absorption was detected at 540 nm using the Synergy plate
reader. The proliferation of cells from MTT studies was expressed
as a percent of control, DMSO-treated cells of the same type.
An inhibitory sigmoidal model was ﬁtted to the experimental
data using Phoenix WinNonlin 6.3 (Pharsight, Mountain View,
CA, USA).
STATISTICAL ANALYSIS
The Kruskal–Wallis tests was used to determine the statistical sig-
niﬁcance of differences (p < 0.05) between experimental groups
(InStat; GraphPad, La Jolla, CA, USA). Data are presented as
means ± SD. Unless otherwise stated, each treatment was applied
in triplicates in two separate studies.
RESULTS
INTERACTIONS OF THE EGFRIs WITH BCRP ATPase
Figure 2 demonstrates the effects of the tested EGFRIs on human
BCRP ATPase activity in Sf9 membrane preparations. ML04,
ML05, ML06, and the two methoxy derivatives of ML03 stimu-
lated the BCRP ATPase, although activation did not exceed 40%
of that produced by geﬁtinib (Figure 2A). PEG-6-ML05 andML10
had no activating effect on ATPase activity. With the exception of
methoxy-Br-ML03, all the compounds inhibited BCRP ATPase to
various extent (Figure 2B).
EFFECTS OF BCRP OVEREXPRESSION ON THE ANTIPROLIFERATIVE
ACTIVITY OF EGFRIs
Madin-Darbey canine kidney II stable transfectants were used to
assess the effect of human BCRP overexpression on the antipro-
liferative activities the EGFRIs (Figure 3). In a separate control
group, 20 μM verapamil was used to block the effect of the
endogenous, canine P-gp present in MDCK cells (Poller et al.,
2011). Inhibition of cell proliferation by ML04, ML06, methoxy-
Br-ML03, and PEG6-ML05 occurred at milimolar concentrations,
and overexpression of BCRP conferred resistance to this effect
(Figure 3). The other tested compounds did not affect the prolif-
eration of MDCK-CT and MDCK-BCRP cells at concentrations
up to 50 μM (data not shown).
EFFECT OF THE EGFRIs ON BODYPY-prazosin ACCUMULATION
Although some of the tested compounds partially inhibited
BCRP ATPase activity, this was not reﬂected in the cellular assay
(Figure 4). Only the positive control, FTC, signiﬁcantly (p< 0.01)
enhanced BODIPY-prazosin accumulation in MDCK-BCRP cells.
None of the compounds signiﬁcantly affected the ﬂuorescent
signal of MDCK-CT cells (data not shown).
RELATIVE BCRP EXPRESSION IN TUMOR CELLS
HCC827 and A549 cells have been previously used for in vivo
imaging of EGFR expression and showed variability in tracer accu-
mulation. The expression of both P-gp and BCRP inA549 cells has
been reported before (Scharenberg et al., 2002). Our analysis con-
ﬁrmed this ﬁnding and further demonstrated BCRP expression in
HCC827 cells. In both cell lines, the extent of BCRP expression
was comparable to that in MDCK-BCRP cells (Figure 5).
DISCUSSION
The increasing need for personalized treatment with EGFRIs pro-
moted the development of novel PET EGFR biomarkers. Indeed,
encouraging results have been obtained through preclinical stud-
ies with both competitive and non-competitive EGFRIs. Yet, the
determinants of probe distribution into tumors are not fully
understood, because the speciﬁcity of tumor signal intensity may
be affected by both the amount of the probe that distributes into
tumor cells and its binding to its cellular targets. This study eval-
uated the interaction of several novel EGFR probes with BCRP, an
ABC transporter that has been previously implicated in EGFRIs
efﬂux (Ni et al., 2010). The BCRPATPase and the BCRP inhibition
assays were conducted at submicromolar concentrations, to reﬂect
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FIGURE 2 | Interactions of EGFRIs with BCRPATPase. (A) Activation of
BCRP-ATPase in Sf9 membrane preparations containing BCRP. Membranes
were incubated with ATP and the tested compounds at 400 nM in the
presence and absence of sodium orthovanadate. (B) Inhibition of
sulfasalazine-stimulated BCRP-ATPase. The effect of EGFRIs was evaluated in
sulfasalazine (10 μM)-stimulated membranes. Data are presented as
means ± SD of the vanadate-sensitive ATPase activity from two experiments
in duplicates.
FIGURE 3 | Effects of BCRP overexpression on the cytotoxicity of EGFRIs
by the MTT assay. Stable MDCKII transfectants of vector alone or vectors
expressing wild-type BCRP were incubated for 72 h with various
concentrations of the indicated compounds. Results are shown as
experimental ﬁndings (circles) and predicted model (line) in MDCK-CT cells
(red), MDCK-BCRP cells (black), and MDCK-BCRP cells treated with 20 μM
verapamil, to block endogenous P -gp activity (green). Data represent the
means ± SD of six replicates.
clinically relevant, unbound EGFRIs plasma levels. This is partic-
ularly the case in PET imaging studies, in which ligand microdoses
may be used.
EGFRIs INTERACTIONS WITH BCRP
Five of the tested compounds, namely ML04, ML05, ML06,
methoxy-ML03, and methoxy-Br-ML03, activated BCRP ATPase
at submicromolar concentrations, suggesting that these com-
pounds are transported by BCRP. The values obtained with
ML10 and PEG6-ML05 could result from inhibition of
basal Pi release (manufacturer’s brochure). A partial over-
lap observed between ATPase stimulation and inhibition indi-
cated that that the evaluated compounds may function as
competitive inhibitors which are also transported substrates
(Eadie et al., 2014).
Compared to the relatively low concentrations which
stimulated the BCRP ATPase, greater EGFRIs concentra-
tions were required to affect the proliferation of MDCK-
CT cells. This reﬂects both the distributional barrier
into cells and the degree sensitivity to the toxic effects
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FIGURE 4 | Effect of EGFRIs on BODIPY-prazosin accumulation. Cell
protein concentration-normalized BODIPY prazosin ﬂuorescence in
MDCK-BCRP cells were evaluated in the presence and the absence of
400 nM of the tested compounds following 1 h incubation. Results are
presented as means ± SD. *Signiﬁcantly different from vehicle-treated cells,
P < 0.01; **Signiﬁcantly different from FTC-treated cells, P < 0.01.
FIGURE 5 | BCRP protein expression in HCC827 andA549 cells.
(A) Representative image demonstrating the intensity of BCRP expression.
(B) Relative β-actin-normalized BCRP expression. MDCK-BCRP and
MDCK-CT cells were used as positive and negative controls, respectively.
n = 4 for each cell type.
of EGFRIs of MDCK cells, which have been shown to
express EGFR (Pick and Wiese, 2012). The mechanisms of
EGFRIs effects on MDCK cell proliferation are currently
unknown, although a recent study reported on the role
of EGFR in mitotic spindle orientation in this cell line
(Bañón-Rodríguez et al., 2014).
At 400 nM, none of the tested compounds increased the
accumulation of BODYPY-prazosin in MDCK-BCRP cells. It is
unlikely that the low plasma concentrations of EGFRIs obtained
upon their administration as microdoses in PET imaging studies
will be involved in pharmacokinetic interactions with P-gp/BCRP
substrates. Yet, BCRP inhibition-based interactions at greater
EGFRIs concentrations cannot be ruled out.
Our study could have been strengthened by using the efﬂux
ratio assay to distinguish between inhibitors and substrates and
to gain a better understanding of the mechanisms that control
the distribution of the compounds of interest into cells. We
used the ATPase assay due to its simplicity, and subsequently
evaluated the cellular effects of the TKIs as a marker of their
BCRP-mediated transport. However, future characterization of
these compounds will involve the use of bidirectional transport
assays.
Due to the relatively small number of molecules evaluated
in our study, it is difﬁcult to assess the impact of structural
modiﬁcations on the molecule interactions with BCRP. Further-
more, BCRP is predicted to have multiple binding sites with
overlapping speciﬁcities (Ni et al., 2010). Thus, the interactions
of substrates with the transporter cannot be precisely identi-
ﬁed. It has been suggested that substrate recognition is based
on global physiochemical properties, such as carbon size length
and lipophilicity, although the importance of log P has been
debated (Ni et al., 2010; Szafraniec et al., 2014). A more sophis-
ticated structure activity relationship study with SN-38 and its
analogs suggested that one amine bound to one carbon of a
heterocyclic ring, fused heterocyclic rings, and two substituents
on a carbocyclic ring of the fused heterocyclic are important
factors in the molecule’s interaction with BCRP (Saito et al.,
2006). That study also predicted a strong interaction of geﬁ-
tinib with BCRP based on these features. Chemical modiﬁcations
such as those aimed to achieve irreversible EGFR binding may
reduce the potency of the EGFRI in binding BCRP. This is sup-
ported by the results obtained in the ATPase activation assay
(Figure 2A). For example, PEGylation of ML04 and ML05, aimed
at reducing their log P with resultant lower non-speciﬁc binding
(Dissoki et al., 2007; Mishani et al., 2008; Mishani and Hagooly,
2009), could have affected the recognition of these compounds
by both BCRP (Figure 2) and P-gp. Nevertheless, no trend was
observed with regard to the relationships between EGFR inhibi-
tion potency or lipophilicity of the compound and its interactions
with BCRP.
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TUMOR CELLS EXPRESSION OF P -gp AND BCRP
Preclinical PET and biodistribution studies in animal bearing
tumor xenografts demonstrated high and sustained uptake of
11C-erlotinib in HCC827, which harbor an activating muta-
tion in exon 19, compared to A549 and NC1358 tumors
(Memon et al., 2009). In order to better understand the impact
of BCRP on the distribution of the studied compounds in
experimental tumor models, we also examined BCRP expres-
sion in HCC827 and A549 cells. In both cell lines, BCRP
expression was comparable to that observed in the positive
control, MDCK-BCRP. Therefore, it appears that the irre-
versible binding of the EGFRI to its intracellular target could
potentially contribute to overcoming the distributional restric-
tion, at least in part, due to relatively longer residence within
cells.
CONCLUSION
Our data suggest that some of the EGFRIs evaluated in this study
interact with BCRP. Whether the compound functions as a trans-
ported substrate or an inhibitormay depend on its concentrations,
the cell type and the experimental or clinical setting. Accordingly,
low radioligand concentrations, in contrast to concentrations
aimed to clinically inhibit EGFRs, could have resulted in a more
pronouncedBCRP/P-gp efﬂux andmay be one explanation for the
failure of some successful targeted EGFRIs as tracer imaging agents
(Mishani et al., 2008). Therefore, using a mixture of radiolabeled
tracer and a “cold” compound to reﬂect clinically relevant con-
centration might improve the outcome of the preclinical imaging
studies.
The relative role of transporter-mediated efﬂux vs. target bind-
ing in probe accumulation within tumors is currently unknown.
To address this issue, the activity of novel compounds devel-
oped as EGFR probes can be tested in vitro in the presence
and the absence of ABC transporters inhibitors. Likewise, given
the expression of BCRP and P-gp in cell lines commonly used
for tumor grafting in small animals, in vivo studies conducted
in the presence and the absence of transporter inhibitors may
help distinguish between pharmacokinetic and pharmacody-
namic contribution to the radioactivity signal within tumors.
Those radioligands which are found to be good P-gp/BCRP
substrates and do not avidly bind EGFRs may be utilized for
in vivo imaging studies of P-gp/BCRP functional activity at
the blood brain barrier. Importantly, further interactions with
other efﬂux transporters (multidrug resistance-associated pro-
teins; MRPs) and relevant uptake transporters should be inves-
tigated in order to better understand the biodistribution of these
probes.
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